Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 35Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 27Lymphoma, Non-Hodgkin 22Burkitt Lymphoma 21Lymphoma, Mantle-Cell 20Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Follicular 19Neuroblastoma 18Myelodysplastic Syndromes 18Multiple Myeloma 18Lymphoma, Large-Cell, Immunoblastic 17Lymphoma, B-Cell, Marginal Zone 17Hodgkin Disease 15Astrocytoma 14Medulloblastoma 13Breast Neoplasms 13Recurrence 12Central Nervous System Neoplasms 12Sarcoma 11Myeloproliferative Disorders 10Leukemia, Myeloid, Chronic-Phase 10Ovarian Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Familial ependymoma 9Carcinoma, Ovarian Epithelial 9Blast Crisis 9Optic Nerve Glioma 8

Interventions

oblimersen 1Razoxane 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Exercise 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cardiotoxicity × Filgrastim × Clear all
NCT00039481 2013-01-17

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡